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Predictive Probabilities In
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John M. Gleason and
Darold T. Barnum*
Introduction
When examining the risks of drug abuse, often the most compelling
statistics relate to accidents, safety, and health. For example, according
to the Federal Railroad Administration, errors attributed to substance-
impaired employees caused 34 fatalities and 66 injuries in 48 separate
incidents between 1975 and 1983.1 In addition to these direct effects,
however, there are also indirect effects, such as the impacts of drug use
on worker productivity, health insurance costs, legal liability, and even
employee-management relations.
Employees who are health-impaired due to substance abuse can be
expected to exhibit lower productivity as a result of performance
deficits, absenteeism, and higher turnover. One estimate of the financial
impact of lost productivity due to substance abuse in the U.S. is $99
billion annually.2
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1 C. CORNISH, DRUGS AND ALCOHOLIN THE WORKPLACE: TESTING AND PRIvACY
(1988). See also,50 Fed. Reg. 31,516 (1985).
2 M. ROTHSTEIN, MEDICAL SCREENING AND THE EMPLOYEE HEALTH COST CRISIS
(1989); RESEARCH TRIANGLE INSTUTE, ECONOMIC COSTS TO SOCIETY OF ALCOHOL
AND DRUG ABUSE (1983); BNA SPECIAL REPORT, ALCOHOL AND DRUGS IN THE
WORKPLACE: COSTS, CONTROLS, AND CONTROvERSIES 7 (1986) [hereinafter BNA
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The health and safety risks of substance abuse can also be expected
to impact insurance costs. Employees with substance-abuse problems,
and their families, are more likely to use medical insurance, and the
employees are more likely to file workers' compensation claims. 3
Estimates of the impact of substance abuse on health insurance
premiums have been as high as $50 billion.4
Drug use has an undeniable effect on employee relations. Employee
dissatisfaction can be caused by perceptions of increased workplace
safety-and-accident-risks associated with substance-abusing colleagues,
and by employee recognition that they are being required to carry a
greater work burden to compensate for illness-and-accident-related
absences of abusers. This employee dissatisfaction requires the
commitment of a variety of extra resources to maintain satisfactory
employee relations.
Finally, there is the issue of legal liability related to the wrongful
acts attributable to employee drug use. Liability resulting from the
activities of health-impaired employees extends to areas such as product
defects, breach of contract, and injuries to employees and non-
employees.
In an attempt to minimize the risks associated with drug abuse,
many employers are resorting to drug testing of employees and job
applicants. Requirements for the testing of certain types of government
employees has accelerated the trend in workplace drug testing.5 There
SPECIAL REPORT]; D. MASI, DRUG FREE WORKPLACE: A GUIDE FOR SUPERVISORS
(Bureau of National Affairs 1987).
3 ROTHSTEIN, supra note 2; MASI, supra note 2.
4 MASI, supra note 2; J. DRIZAY, FIFiY-BLUON DOLLAR DRAIN: ALCOHOL,
DRUGS& THE HIGH COST OF INSURANCE 37 ( P. Dilday-Davis ed. 1986).
5 CORNISH, supra note 1; Procedures of Transportation Workplace Drug Testing
Programs, 49 C.F.R. Part 40; Glantz, A Nation of Suspects: Drug Testing and the
Fourth Amendment, 79 AM. J. PUB. HEALTH 1427-1431 (1989); Dubowski, The
Role of the Scientist in Litigation Involving Drug-Use Testing, 34 CLINICAL
CHEMISTRY 788-792 (1988).
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is some evidence that drug testing programs are useful in reducing the
costs associated with the direct and indirect types of health and safety
risks we have examined. For example, drug testing at Illinois Bell
Telephone Company, and a subsequent rehabilitation program, is
credited with leading to savings of $459,000 in reduced absences,
accidents, and medical and disability benefits. 6
The types of risks discussed thus far are the risks associated with
having drug-impaired employees. However, there are also risks
associated with drug-testing programs designed to eliminate such
employees through identification leading to refusal to hire, or employee
rehabilitation or termination. Ill-conceived or ill-conducted testing
programs may result in legal liability for invasion of privacy,
defamation, wrongful discharge, emotional distress/outrageous conduct,
negligence, unreasonable publicity and false light, or other torts.7
And, if falsely-accused workers are terminated, at the very least the
employer loses the services of an acceptable employee.
Thus, if testing is not conducted or if the tests do not identify all
drug abusers, then management faces certain risks arising from the
activities of drug-impaired employees. On the other hand, if testing is
conducted and some drug-free employees are falsely identified as drug
users, then a different set of risks arises from potential legal actions of
the falsely-accused workers, and from terminations of the falsely-
accused drug-free employees.
In both cases, it is necessary to identify the costs of the events and
their probabilities of occurrence. That is, to analyze the risks involved, it
is necessary to identify: (1) the costs of events associated with drug-
abusing employees; (2) the probabilities that employees will abuse drugs
when testing is used, and when testing is not used; (3) the costs of
6 DEcRESCE, LIFSHz, MAZURA & TILSON, DRUG TESTING IN THE WORKPLACE
(1989) [hereinafter DRUG TESrNG].
7 CORNISH, supra note 1; ROTHSTEIN, supra note 2.
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events associated with falsely accusing employees of using drugs; and
(4) the probabilities of such false accusations.
This paper deals with the last of these four factors: the probability of
falsely accusing employees of drug abuse. It is divided into sections
addressing: the terminology to be employed, drug usage rates for
employees in certain workplaces, laboratory proficiency studies, and
Bayesian analyses of proficiency-study and drug-usage data. We review
the concepts of accuracy that are most relevant and apply these concepts
to data on drug usage by employees in certain workplaces, thereby
identifying the potential problems that could occur in routine employee
drug-testing programs. The clearest conclusion of this analysis is that
seemingly accurate tests for abused drugs may, in fact, be inaccurate to
a disturbingly high degree, under circumstances potentially present in
many workplaces.
Terminology
When a specimen is tested for drugs, one of four outcomes must
occur:
* true positive: specimen with drugs tests positive for drugs
* true negative: specimen with no drugs tests negative for
drugs
• false positive: specimen with no drugs tests positive for
drugs
* false negative: specimen with drugs tests negative for
drugs.
Given that a specimen contains drugs, it must test either positive or
negative. That is, the probability of a positive test result (given drugs are
present) plus the probability of negative test result (given drugs are
present) must equal 1.0. This may be written:
P(+IDrugs) + P(-IDrugs) = 1.0
In other words, when drugs are present in a specimen, the probabilities
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of a true positive and a false negative must total one.
Likewise, a specimen without drugs must test either positive or
negative. That is, when no drugs are present, the test must result in
either a false positive or a true negative. This may be written:
P(+INoDrugs) + P(-INoDrugs) = 1.0
Now, let us trn to three measures of drug test accuracy that are
used in the health-related professions: sensitivity, specificity, and
predictive value. Sensitivity is the probability that a specimen with drugs
will test positive. Thus, it is equal to the probability of a true positive,
or:
Sensitivity = P(+IDrugs)
A second concept used in evaluating the accuracy of tests and labs is
"specificity." Specificity is the probability that a drug-free specimen will
test negative, or the probability of a true negative:
Specificity = P(-INoDrugs)
Thus, sensitivity indicates the ability of the test to correctly report the
presence of drugs, while specificity indicates the ability of the test to
correctly report the absence of drugs.
In drug testing we are most concerned with incorrect results, that is,
with false positives and false negatives. Sensitivity and specificity,
however, are indirect indicators of the false result rates. That is, the
probability of obtaining a false positive, P(+INoDrugs), is equal to (1 -
Specificity). And, the probability of obtaining a false negative,
P(-IDrugs), is equal to (1 - Sensitivity). As can be seen, the higher the
sensitivity rate, the lower the false negative rate. Likewise, the higher
the specificity rate, the lower the false positive rate. What we would like
for labs to do, therefore, is to maximize sensitivity and specificity,
because this will minimize the false negative and false positive rates.
Another important concept, although not used in studies measuring
laboratory proficiency, is the "predictive value" of a test. In the case of a
drug test, the positive predictive value is the probability that the drug is
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present in a specimen, given that the test yielded a positive result, that
is, the posterior probability resulting from a Bayesian analysis:
Positive Predictive Value = P(Drugsl+)
For example, if 90 out of every 100 people testing positive for drugs
truly have drugsin their systems, then the positive predictive value of
the test would be 0.90. And, the probability that persons with positive
test results truly do not have drugs in their systems would be 0.10. That
is, if a drug test has a positive predictive value of X, then the probability
is (1 - X) that a person who tests positive is, in truth, drug free. Thus,
by maximizing the positive predictive value of a test, we also minimize
the probability that specimens testing positive are truly drug free.
The importance of this concept is readily apparent, because it is the
key to determining whether a positive result on a drug test provides
sufficient evidence of drug usage. If, for example, positive results on a
test are known to be untrue in one out of every ten cases, then a positive
test probably would not be considered sufficient evidence of drug use.
More importantly, if one wishes to protect the innocent from false
accusation, then it is the positive predictive value of the test that is of
prime concern.
Specificity, sensitivity, and predictive values may be stated as either
probabilities or as percentages. 8 In this paper, we use both
percentages and probabilities, as the context dictates.
Drug Usage Rates
Not surprisingly, estimates of drug usage vary widely. Because
using drugs of abuse usually is illegal, but often is considered to be in
style, self reports may not be too reliable. Likewise, many of those
making pronouncements about the extent of drug abuse have strong
8 ROTHSrIN, supra note 2; DRUG TESTING, supra note 6; B. ROSNER.
FUNDAMINTALS OF BIOSTATIs'iCS (2nd ed. 1986).
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incentives for showing that drug usage is at one extreme or the other.
Finally, the characteristics of the group about which the estimates are
made can cause wide variations, because drug usage varies significantly
based on age, geographic location, and other variables. Considering
these caveats, we provide several estimates of the extent of drug use in
various workplaces.
The National Institute on Drug Abuse (NIDA), estimates, based on
self-reports, that 7.0% of Americans over the age of 12 used some
illegal substance at least once during the month prior to the NIDA 1988
household survey,9 although this percentage drops sharply for people
over 35 years old. 10
A Department of Labor (DOL) report11 looked at the workforce
only, and based its estimates on the results of employer drug tests. For
the industries surveyed in 1988, 8.8% of employees tested positive,
with the employees of the smallest firms tending to have the lowest
positive rates; furthermore, 11.9% of all job applicants tested positive.
The DOL report also provides data on positive test results in various
industries. Wholesale trade had the highest employee positive rate,
20.2%, whereas retail trade had the highest applicant positive rate,
24.4%. Employee (applicant) rates for various segments of the economy
are: wholesale trade 20.2 (17.4), retail trade 18.8 (24.4), services 3.1
(9.9), and communications and public utilities 7.8 (5.5). Notice that in
some cases the positive rate for applicants is higher than for current
employees, while in other cases it is lower.
In the 1986-87 period, tests of railroad workers involved in train
9 Study Finds Overall Drug Reduction But Dramatic Rise In Cocaine, Crack, 3
The National Report on Substance Abuse (Aug. 2, 1989) [hereinafter Study].
10 Study, supra note 9; NATIONAL INSTrUTE ON DRUG ABUSE, U.S. DEPARTMENT
OF HEALTH AND HUMAN SERVICES, DHHS Pub. No. (ADN) 87-1539, NATONAL
HOUSEHOLD SURVEY ON DRUG ABUSE: POPULATION ESTIMATES FOR 1985 (1987).
11 BUREAU OF LABOR STATISTICS, U.S. DEPARTMENT OF LABOR, BUREAU, REPORT
760 SURVEY OF EMPLOYER ANTI-DRUG PROGRAVS (1989).
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accidents revealed that 29 of the 759 people, or 3.8%, tested positive for
drugs of abuse. 12 These were not random tests, of course, but tests
administered under conditions where one would expect drug usage to be
higher than usual.
The U.S. Department of Transportation randomly chose and tested
more than 16,000 of its employees between July 1, 1988 and June 30,
1989. Of these, 99 tested positive, for a rate of 0.619%. 13
Finally, results of tests of 3,600 employees of the U. S. Customs
Service show a drug usage rate of 0.139%.14
Accuracy of Drug Testing
A topic no less subject to disagreement than the proportion of
workers utilizing drugs is the accuracy of the tests for such substances.
It appears that estimates of accuracy sometimes may be motivated more
by the self-interest of the claimant than by sound empirical evidence. On
the other hand, a variety of factors can cause large variations in
accuracy, such as characteristics of the laboratories involved,
concentrations of the drugs in spiked challenges, whether proficiency
tests are open or blind, and other similar influences.
Because of the concerns over whether current testing correctly
predicts the presence and absence of drugs, a number of studies have
been conducted in which prepared samples have been sent to
laboratories to determine the accuracy of their testing procedures.
Rather than review all of the laboratory proficiency studies,
estimates from two articles published in the Journal of the American
Medical Association (JAMA) are utilized.15 We consider the studies on
12 Drug tests are lousy, 69 Labor 1-4 (Apr. 29, 1987).
13 DOT Did Not Obey HHS Rule, GAO Tells Senator in Report, 3 The National
Report on Substance Abuse (Nov. 8, 1989).
14 Court Backs Tests of Some Workers to Deter Drug Use, N. Y. Times, Mar. 22,
1989, National ed., at 1.
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which these articles are based to be the two best available to date. They
were well-designed, with rigorous protocols, and were conducted by
independent investigators. Also, very importantly, they include results
of blind tests, where the laboratories were not aware that they were
being tested.
The 1985 JAMA study reported the results of a series of blind and
open proficiency tests for various drugs of abuse conducted in 1981 by
the Centers for Disease Control in conjunction with the NIDA. The
1988 study reported on the blind and open proficiency tests of labs
conducted by the NIDA in 1986-1987. Both studies used relatively
large samples of labs with substantial experience in testing for abused
drugs. Although it appears that these labs are likely to be better than
most of the drug testing labs in the country, they are not likely to be
representative of the very best either. That is, the results of these studies
represent what could be expected from sound, well-established and
experienced drug testing laboratories. Although the 1988 study may be
more representative of recent experience, it can be expected that labs
similar to those reported on in the 1985 study still exist.16
The results of open tests, those involving urine samples that labs
knew were being used for quality checks, are not reported herein.
Results of blind tests, those in which the labs did not know they were
being tested, are much more representative of what one could typically
expect if actual urine samples were submitted. Therefore, only blind test
results are utilized herein.
Based on our calculations from data presented in the articles, the
false positive rate (false positives/negative challenges), was 0.014 in the
1985 JAMA article, and 0.002 in the 1988 JAMA article, representing
15 Hansen, Caudill & Boone, Crisis in Drug Testing: Results of CDC Blind
Study, 252 J.A.M.A. 2382-2387 (1985); Davis, Hawks & Blanke, Assessment of
Laboratory Quality in Urine Drug Testing: A Proficiency Testing Pilot Study, 260
J.A.M.A. 1749-1754 (1988).
16 BNA SPECAL REPORT, supra note 2.
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findings on the proportions of drugless samples where drugs were
incorrectly reported to be present. These statistics are estimates of
P(+INoDrugs), and are equivalent to specificity levels of 98.6% and
99.8%, respectively. The false negative rates, (false negatives/positive
challenges) were 0.618 in the 1985 study and 0.311 in the 1988 study.
These statistics estimate the P(-Drugs), and reflect sensitivity levels of
38.2% and 68.9%, respectively. 17
It should also be noted that the results from the 1988 study are based
upon testing processes in which confirmation tests were conducted -
that is, the initial positive result was confirmed by another test. The
extent of confirmation testing in the 1985 study is uncertain. In fact,
much of the difference between the rates from the two studies may be
the result of confirmation testing.
Bayesian Analyses
Employers should take reasonable care to ensure that employees are
not falsely accused of drug use due to questionable test results. But, if
99% of drug-free employees test negative, then many employers would
conclude that reasonable doubt does not exist when an employee tests
positive. Since the percentages of the drug-free specimens testing
positive in the JAMA studies were 98.6 and 99.8%, it may appear that
drug tests are accurate enough that reasonable doubt could not be
established.
However, the results are not what they seem, as Bayesian analyses
of AIDS test and transit drug test results have exhibited. 18 Consider the
17 A "negative challenge" is a specimen that does not contain a drug being tested
for by the challenge, and a "positive challenge" is a specimen that does contain a drug
being tested for by the challenge.
18 Gleason, Perceived Fairness in Risk Management: Bayesian Implications for
AIDS Testing, 9 RISK ANALYSIS 15-16 (1989); Gleason & Schweig, Probabilistic
Reasoning in Underwriting Decisions Regarding Routine AIDS Testing, 42 J. AM.
SoCy CLU & ChFC 86-91 (1988); Barnum & Gleason, Reliability of Workplace
Gleason and Barnum: Probabilities in Employee Drug Testing 13
first case in Table 1.
Table 1
Application of Bayesian Analysis to Drug Test Data
[1] [2] [3] [4] [5] [61 [71





















































































Drug Testing: Organizational Implications, in PROCEEDINGS OF THE MIDWEST
BUSNESS ADMISTRATION ASSOCIATmiN 11-13, Chicago, IL, Mar. 1989; Barnum &
Gleason, Accuracy in Transit Drug Testing: A Probabilistic Analysis,
TIANSPORTATiON RESEARCH RECORD, No. 1270, 1990, in Press.
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As shown for Case 1 in columns 2 and 3 of the table, a urine
specimen must either contain drugs (SI) or contain no drugs (S2 ). For
this case, it is assumed that the probability is 0.088 that the urine
specimens truly contain drugs, requiring that the probability be 0.912 (1
- 0.088) that they do not, as shown in column 4. These probabilities
imply that 8.8% of the target population uses drugs; recall that this is the
positive drug test rate for all current employees in the DOL survey. We
use this rate as a prior probability for illustrative purposes only. Its use
in this manner, of course, assumes high reliability in the DOL tests.
The next column, column 5, identifies the probability of the urine
specimen testing positive for drugs when there truly are drugs present
(0.382), and when there truly are no drugs in the sample (0.014). That
is, P(+INoDrugs) = 0.014, and P(+IDrugs) = 0.382. These probabilities
are taken from the 1985 JAMA study.
The numbers in the sixth column are the products of the numbers in
the two previous columns. That is, for the population being tested, the
probability that a person truly is on drugs and tests positive for drugs is
0.034, while the probability that a person truly is not on drugs and tests
positive for drugs is 0.013. Note that the sum of these two probabilities,
denoted by P(+) and equaling 0.047, is the probability of a positive test
result.
Dividing each of the numbers in the sixth column by P(+) yields the
numbers in the seventh column, which are the probabilities of truly
being in the particular states, given a positive test result. Thus, the
probability that specimens that test positive will truly contain drugs is
0.723, meaning the test has a positive predictive value of 72.3%. And,
the probability that specimens that test positive will truly contain no
drugs is 0.277. That is, P(Drugsl+) = 0.723, and P(NoDrugsl+) =
0.277.
These same results can be developed more intuitively by considering
a group of 1,000 employees who are tested for drug usage. If 8.8% of
Gleason and Barnum: Probabilities in Employee Drug Testing 15
the group are truly taking drugs, then 1000 * 0.088 = 88 will provide
urine specimens that contain drugs, and the remaining 912 will provide
specimens that are drug-free. Of the specimens containing drugs, 88 *
0.382 = 34 will test positive for drugs, and the remaining 54 will test
negative. Likewise, of the specimens not containing drugs, 912 * 0.014
= 13 will test positive for drugs, and the remaining 899 will test
negative. Thus, a total of 34 + 13 = 47 specimens will test positive for
drug usage, whereas 13 of these 47 do not actually contain drugs. That
is 13147 = .277 (or 27.7%) of those testing positive for drug usage truly
will be drug free.
Thus, more than one out of every four applicants testing positive
truly will be drug free! With probabilities such as these, it is highly
unlikely that a positive drug test would provide a preponderance of
evidence that an individual was taking drugs, let alone meet higher
levels of proof, such as clear and convincing evidence or evidence
beyond a reasonable doubt. It would seem illogical, from the standpoint
of good personnel practice, to eliminate an applicant on the basis of such
unreliable evidence. Of course, the actual probabilities that a person who
tests positive is not on drugs will differ under different assumptions
about the percentage of the target population that is actually taking
drugs, test specificity, and test sensitivity. Some different assumptions
are presented in Cases 2 through 6. Recall that in Case 1 we assumed
8.8% of the population being tested actually had drugs in their systems.
In Case 2 and Case 3, we use different estimates of the proportion of the
target population on drugs. While the Case 1 estimate was based on
results of tests of all job applicants in the DOL survey, the Case 2
estimate (20.2%) is based on test results for applicants in wholesale
trade, and the Case 3 estimate (0.1%) is based on the aforementioned
test results for U.S. Customs Service employees. 19
19 See supra note 14.
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In Cases 4, 5, and 6, we repeat the same three rates of drug usage
(0.088, 0.202, and 0.001), but we substitute the 1988 JAMA article
estimates of sensitivity and specificity, namely 68.9 and 99.8% (which
represent, respectively, a false negative rate of 0.311 and a false positive
rate of 0.002).
Thus, for Cases 1, 2, and 3, respectively, about one out of every
four positives represent those who have not taken drugs when all
employees are considered, one out of every eight positives represent
drugless employees in wholesale trade, and 97 out of 100 positives
represent drugless Customs Service employees. Under any of these
circumstances, the positive test results have no value in proving drug
use. If they are used in such a manner, great injustice will be done to
many drug-free employees.
The error rates are lower for Cases 4, 5, and 6, where we use
sensitivity and specificity rates from the 1988 JAMA article. In these
three cases, 1 out of every 30 employees who test positive will be
falsely accused, as will 1 out of every 70 employees in wholesale trade,
and 3 out of 4 Customs Service employees. Although these results are
better than those based on sensitivity and specificity rates from the 1985
JAMA study, there is still a relatively high error rate. And, because each
of these scenarios may be applicable to some workplaces, error rates
easily could be as high as the 97% figure from Case 3.
All of these six cases use sensitivity, specificity, and drug usage
rates that may be found in some workplaces. However, because of the
more rigorous standards required at the few NIDA-certified labs, it can
be expected that such labs have higher accutacy rates. Thus, while our
examples indicate what can happen in some circumstances, they should
serve primarily to exemplify the process, and should not be considered
to be representative of the expected results for any specific organization.
That is, our results should serve to illustrate the types of inaccuracies
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that might occur. Each organization must identify its own sensitivity,
specificity, and drug usage rates, in order to develop the false conviction
rate applicable to the organization.
Conclusions and Policy Implications of the Study
The clearest conclusion of this analysis is that allegedly-accurate
tests for abused drugs may sometimes be inaccurate to a disturbingly
high degree, under circumstances that may be present in many
workplaces. Thus, both government regulators and employers should
proceed slowly and with the utmost care in implementing drug testing
policies, and they should consider the Bayesian implications of their
proposed testing policies.
More specifically, results of employee drug tests should not be used
as a basis for actions against employees, unless positive results are
confirmed, e.g., with a gas chromatography/mass spectrometry test.
However, remember that the false results from the 1988 JAMA study
incorporated the use of confirmation testing, including the frequent use
of the gas chromatography/mass spectrometry test, which is alleged to
be highly accurate.
Note that the proportion of people falsely accused increases when a
lower percentage of the population being tested is truly on drugs. Thus,
positive results of employee drug tests conducted in environments
where low drug usage rates could be expected (for example, tests of
Customs Service employees) should be viewed with more skepticism
than positive results in other environments (such as wholesale trade).
This paper has utilized accuracy data from good labs, where chain of
custody was not a problem, and where there were no non-drug
substances that could produce positive test results, since all challenges
contained only the drugs to be tested for. If any of these factors come
into play, then the reliability of the results will be even worse than those
2 RISK - Issues in Health & Safety 3 [Winter 1991]
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presented.
The use of abused drugs by the nation's workers is a serious
problem that must be addressed on many fronts. In the proper
circumstances, urine testing is a valuable weapon in slowing drug use.
However, while testing should be available, it should be used sparingly
and with the utmost care. In particular, it is critical that appropriate
accuracy information be developed, using data specific to each
organization that utilizes drug testing. Otherwise, the potential benefits
of the testing derived from improved health and safety may be offset by
the losses growing out of the false positive results.
